Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate ‐to‐Severe Rheumatoid Arthritis

ConclusionThe ACR20 response rate at week 24 was equivalent between patients treated with the biosimilar agent SB5 and those treated with reference ADA. SB5 and reference ADA were both well tolerated, with comparable safety profiles, in patients with RA.

Source: Arthritis and Rheumatism - November 21, 2017 Category: Rheumatology Authors: Michael E. Weinblatt, Asta Baranauskaite, Jaroslaw Niebrzydowski, Eva Dokoupilova, Agnieszka Zielinska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz ‐Rosiak, Soo Yeon Cheong, Jeehoon Ghil Tags: Original Article Source Type: research